Wilms Tumor Survivors at Increased Risk of Breast Cancer
Survivors who received radiation to the chest were more likely to develop breast cancer.
Breast cancer screening guidelines should be reevaluated for women who survived treatment for pulmonary metastases from Wilms tumor, according to a study published early online in the journal CANCER.
Researchers from the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle, Northwestern University in Chicago, Illinois, and St. Jude's Children's Research Hospital in Memphis, Tennessee, investigated whether female survivors of Wilms tumor had an increased risk of breast cancer, following radiotherapy for the disease.
The researchers identified 2,492 girls who had participated in the National Wilms Tumor Studies 1 through 2 (1969 to 1995), and who were followed from the age of 15 until mid-2013. Usual treatment was a relatively low dose of 12-14 Gray of radiation therapy to the entire chest.
The results showed that over 20% of female Wilms tumor survivors who received radiation to the chest, developed breast cancer by age 40 (75% of this group had invasive cancer). However, only 0.3% of female Wilms tumor survivors who did not receive radiation developed breast cancer. There was an intermediate risk (4%) of breast cancer among female Wilms tumor patients who had received abdominal radiation, but no chest radiation. The standard incidence ratios for females receiving chest irradiation, abdominal radiation, and no radiation were 27.6, 6.0, and 2.2 compared to the general population.
"Current guidelines call for early screening for breast cancer among survivors of childhood cancer if they have received 20 or more Gray of radiation therapy to breast tissue. This would exclude a large majority of patients who had received whole chest radiation for Wilms tumor," coauthor Norman Breslow, PhD, University of Washington and the Fred Hutchinson Cancer Research Center, said in a release. "Our results suggest that the risk of early breast cancer among Wilms tumor survivors is sufficiently high that early screening might be considered an option for them also."
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
ECR Mammography Study: Pre-Op CEM Detects 34 Percent More Multifocal Masses than Mammography
February 28th 2025In addition to contrast-enhanced mammography (CEM) demonstrating over a 90 percent detection rate for multifocal masses, researchers found that no significant difference between histological measurements and CEM, according to study findings presented at the European Congress of Radiology.
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.
